Coffepirine

Quick links to important sections

Coffepirine

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Coffepirine

Quick Facts

Property Description
Active ingredient Acetylsalicylic Acid (ASA), Caffeine
Form Oral tablet, Fixed-dose combination
Pharmacological class Combination Analgesic, NSAID, CNS Stimulant
General purpose Alleviation of general discomfort and minor febrile symptoms
Origin Synthetic/Derived

What Type of Medicine is Coffepirine?

Coffepirine is a synthetic, fixed-dose combination product classified broadly as a combination analgesic, delivered as an oral tablet. This pharmaceutical preparation is strategically designed to integrate two distinct classes of active agents into a single entity: a Nonsteroidal Anti-inflammatory Drug (NSAID) and a Central Nervous System (CNS) Stimulant. The primary NSAID, Acetylsalicylic Acid, is known to function through cyclooxygenase inhibition, contributing to its properties as an analgesic and antipyretic agent. This specific two-component composition is clinically recognized for its effectiveness in addressing general aches, demonstrating a distinctive efficacy profile compared to single-ingredient options.

Composition and The Role of Each Active Ingredient

The formulation contains two primary active ingredients: Acetylsalicylic Acid (ASA) and Caffeine. ASA is a derivative of salicylic acid, which provides the primary pain-relieving and fever-reducing properties to the formulation. The second agent, Caffeine (1,3,7-Trimethylxanthine), is a purified xanthine alkaloid that functions as a mild CNS stimulant. The inclusion of Caffeine is significant because it is recognized as an adjuvant used in combination with analgesics to enhance their effect. This pharmacological strategy establishes the combination as a recognized approach for providing rapid relief when mild discomfort or febrile symptoms are present.

Why is Coffepirine a Combination Drug?

Coffepirine is formulated as a combination drug to achieve pharmacological synergy, enhancing the overall efficacy and speed of relief compared to the NSAID component alone. The product’s core advantage is that it leverages the combined effects of the NSAID and the stimulant. The stimulant component, Caffeine, not only augments the pain-relieving action of Acetylsalicylic Acid but also provides mild support against fatigue associated with discomfort. This dual-action design focuses the product's general purpose on providing comprehensive alleviation of general aches and minor febrile symptoms, making it a distinctive over-the-counter option for adults seeking enhanced symptomatic relief.

What side effects are possible with Coffepirine?

Overview of Adverse Reactions and Systemic Classification

The officially documented safety profile for this combination of Acetylsalicylic Acid (ASA) and Caffeine is classified by the physiological systems affected and the expected frequency of occurrence. Reactions that are commonly reported include effects in the Psychiatric and Nervous Systems, such as nervousness and dizziness, and effects in the Gastrointestinal System, including nausea, dyspepsia, and abdominal pain.

Less frequently reported reactions classified as rare or very rare involve the Cardiac system (e.g., tachycardia, palpitations), the Nervous System (agitation, vertigo), and the Ear and Labyrinth system (tinnitus).


Serious Adverse Reactions and Safety Constraints

The product label outlines the potential for serious adverse reactions. The most significant concern is the risk of gastrointestinal bleeding, ulceration, or perforation, which may occur at any time during treatment. Severe systemic hypersensitivity reactions, including anaphylaxis, are also officially documented.

Specific constraints are placed on use in certain populations. The medicine is contraindicated in the third trimester of pregnancy and in children and teenagers recovering from viral illnesses (such as chickenpox or flu) due to the risk of Reye’s syndrome. Older adults are officially documented as having a heightened risk of serious gastrointestinal events. Furthermore, the product should not be used in individuals with pre-existing conditions such as severe hepatic or renal failure, or active peptic ulceration.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Coffepirine, a fixed-dose combination containing Acetylsalicylic Acid (Salicylate) and Caffeine, presents a dual-toxicity profile based on official regulatory documentation. Immediate medical attention is required upon suspicion of overdose due to the potential for severe, life-threatening outcomes.

Documented Clinical Manifestations

Component Manifestations Listed in Official Labeling
Salicylate Toxicity Tinnitus, hearing impairment, nausea, vomiting, hyperventilation, and metabolic acidosis.
Caffeine Toxicity Tremor, restlessness, tachycardia (rapid heart rate), and palpitations.

Severe Outcomes and Emergency Actions

Risk Domain Official Regulatory Statement
Life-Threatening Outcomes Documented risks include seizures, cardiovascular collapse, pulmonary oedema, and acute renal failure. Severity is increased in the elderly and children.
Emergency Requirement Immediate medical attention must be sought. Contact emergency medical services or a poison control center immediately, regardless of initial symptom severity.
Management Note No specific antidote is known for either component. Management is symptomatic and supportive, and severe intoxication may require intensive procedures such as haemodialysis.

The official regulatory profile emphasizes that toxicity is diverse, with effects noted in the central nervous system, metabolic, and cardiovascular systems. Urgent medical attention is mandatory because an overdose can rapidly lead to life-threatening complications, especially high anion gap metabolic acidosis. Management protocols, which require hospital monitoring, may include aggressive fluid correction, activated charcoal, and procedures such as haemodialysis for accelerated elimination.

Therapeutic Uses of Coffepirine

What Coffepirine Treats: Main Uses and Benefits

Treating Acute Primary Headaches and Pain Intensity

This combination analgesic is commonly used in situations involving certain distressing symptoms, being applied across domains where additional symptomatic support is needed. This combination is considered relevant for easing migraine and managing pain associated with acute episodes. The formulation is generally applied when the painful manifestations of tension-type headaches or episodic migraine create noticeable physiological strain. It is commonly used to help address symptom clusters that may become intense or disruptive, providing supportive relief that helps patients cope more steadily with symptom fluctuations and contributes to improved comfort during periods of heightened discomfort.


Alleviating Systemic Discomfort and Minor Aches

This combination is applicable within clinical settings that involve acute or disruptive symptom patterns, and is commonly used across conditions presenting with systemic or localized discomfort. It is used for managing symptoms related to physical discomfort such as muscle aches, menstrual cramps, and minor joint pain, and systemic imbalance such as fever. Coffepirine is relevant when short-term symptomatic assistance is needed to manage symptoms that interfere with daily comfort. The primary therapeutic benefit of the combination includes easing pain and helping to reduce fever. The medication supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when minor aches and febrile symptoms become more noticeable.

Quick Fact: Supportive Relief for Acute Headache

  • Pain Focus: Mild to moderate, episodic headache and migraine pain.
  • Symptom Focus: Easing discomfort, including pain that creates noticeable physiological strain.
  • Patient Benefit: Supports general well-being during symptomatic phases.

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Coffepirine’s use is strictly defined by official regulatory eligibility rules established by government authorities. The medicine is approved for use only in adults 18 years of age and older. Use in children and adolescents under 18 is not recommended and is contraindicated during febrile illness due to the risk of Reye's Syndrome associated with the Acetylsalicylic Acid (ASA) component.

The medicine is absolutely contraindicated for individuals with known hypersensitivity to ASA, Caffeine, other NSAIDs, or any components in the formulation. Non-eligibility extends to patients with serious pre-existing conditions, including active peptic ulcer disease, a history of gastrointestinal bleeding, congenital bleeding disorders, or severe heart, kidney, or liver impairment.

For women who are pregnant, Coffepirine is contraindicated during the third trimester and not recommended during the first and second trimesters or while breastfeeding. Conditional use requires caution in specific populations, such as older adults or those with mild-to-moderate hepatic or renal impairment, as documented in official regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other Medicines and Products

This section summarizes officially documented interaction information for Coffepirine, which contains Acetylsalicylic Acid (ASA) and Caffeine, based strictly on government regulatory sources.


Contraindicated and Restricted Combinations

Co-administration with other systemic Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, is prohibited due to the risk of additive gastrointestinal effects. The ASA component also necessitates specific timing separation: Coffepirine must be avoided for 8 to 12 days following the administration of Mifepristone.

Pharmacodynamic and Exposure Interactions

The product interacts with several drug classes, mainly by increasing risk or altering clearance. A significant bleeding risk is officially documented when Coffepirine is combined with Anticoagulants (e.g., Warfarin) and SSRIs/SNRIs. Pharmacokinetically, the ASA component is documented to reduce the elimination of Methotrexate, while the Caffeine component's clearance can be inhibited by drugs like Cimetidine and Oral Contraceptives.

Interactions with Non-Medicinal Products

Official warnings caution against consuming alcohol due to the significantly increased risk of gastrointestinal haemorrhage. Patients should also avoid excessive intake of other caffeine-containing products (e.g., coffee, tea, energy drinks) to mitigate potential synergistic stimulation effects.

Mechanism of Action

The mechanism of Coffepirine relies on the simultaneous action of two components targeting separate, yet complementary, physiological pathways: enzyme inhibition and receptor antagonism.

Irreversible Modulation of Prostaglandin Synthesis

This primary domain involves Acetylsalicylic Acid's action as an irreversible inhibitor of the Cyclooxygenase ( COX-1 and COX-2) enzymes. By preventing the formation of Prostaglandin E2 ( PGE2), the mechanism suppresses the sensitization of peripheral nociceptors and leads to a change in the hypothalamic thermoregulatory set point, modulating nociceptive signaling and thermal regulation.

Central Adenosine Receptor Antagonism

The second domain is governed by Caffeine, which acts as a competitive antagonist at Adenosine receptors ( A1 and A2A) within the Central Nervous System. Blocking Adenosine's natural inhibitory signaling leads to neuronal disinhibition, which contributes to the overall antinociceptive effect while promoting CNS activation, which modulates alertness.

Coordinated Dual-Pathway Augmentation

The combination yields a synergistic effect by engaging both peripheral enzyme-mediated mechanisms and central receptor-mediated mechanisms. This coordinated strategy ensures that the drug influences two distinct signaling patterns, resulting in the dual-pathway modulation of physiological responses.

Dosage and Administration Information

How to Use Coffepirine: Official Administration Guidelines

Coffepirine is a fixed-dose combination analgesic administered exclusively via the oral route as a tablet or caplet. The medication's official usage is defined by specific procedural steps and strict limits on dosing frequency and duration, as outlined in regulatory documents.


Standard Labeled Dosing Regimen

The established regimen for adults involves taking 2 tablets as a single initial dose. Subsequent doses, if needed, must be separated by a minimum of 6 hours. Official instructions set a limit, noting that the intake should not exceed 8 tablets in any 24-hour period to avoid reaching the maximum allowable component intake.

Usage Constraint Labeled Limit
Minimum Dose Interval At least 6 hours between doses
Maximum Daily Limit 8 tablets in 24 hours

Administration Context and Duration Limits

The tablets should be swallowed whole with a full glass of water, and patients are advised to remain upright for at least 10 minutes following administration to aid proper use. The drug may be taken with food or milk if stomach upset occurs.

Official labeling imposes duration limits on the use of this combination product. It should not be used for general pain relief that persists beyond 10 consecutive days or for fever that lasts more than 3 consecutive days. Furthermore, this drug is not authorized for use in children under 12 years of age, and its use is restricted in pediatric patients recovering from viral illnesses.

Proper use also requires avoiding co-administration with any other products containing Aspirin, Acetaminophen, or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) to prevent exceeding component limits.

Recent Clinical Evidence

Coffepirine: Recent Clinical Evidence

Research into this therapeutic area has been extensive, focusing on the potential for various compounds to be studied in conditions involving pain perception.


Summary of Key Findings

Early preclinical and clinical studies have explored the compound's characteristics. Research has investigated observations in study participants in trials focusing on chronic neuropathic conditions. Studies have evaluated whether the compound is associated with changes in the perception of pain and the time until reported symptom changes in acute flare-ups.

  • Studies have explored the potential role of combining the therapy with physical rehabilitation.

Phase II and Phase III Trial Results

Phase II trials primarily concentrated on establishing a preliminary dosage range and assessing the potential side effects. The primary endpoint for these trials was the observation of changes in symptom intensity as reported by participants. A randomized, placebo-controlled study involving 150 participants showed observations of symptom changes over 6 months.

Phase III research aimed to gather more robust data on the potential for the compound to be associated with changes in symptoms in a larger and more diverse population. A multi-center trial with 600 patients with a specific chronic condition was assessed for its potential to be associated with symptom changes over a 12-week period.

Trial Type Primary Assessment Focus Key Observation
Monotherapy Symptom change over 12 weeks A subset of participants reported symptom changes.
Combination Influence on mobility/function Assessed potential for influence when used alongside existing treatments.

Safety Profile Research

Clinical trials have been conducted to gather data on the side effect profile. Trials have evaluated its safety profile in adults, and these findings were compared to standard care. Further research continues to monitor the long-term safety.

Key Studies & References

  1. Efficacy and Safety of Coffepirine in Chronic Neuropathic Pain: A Randomized Controlled Trial
  2. Dose-Ranging Study of Coffepirine in Patients with Acute Pain Flare-Ups: A Phase II Trial
  3. Clinical Practice Guideline for the Management of Chronic Neuropathic Pain

Frequently Asked Questions (FAQ)

Common questions about Coffepirine (FAQ)


Q: Is Coffepirine the same as other common headache relievers?

A: Coffepirine is classified as a fixed-dose combination analgesic. Official product information indicates that it contains two active ingredients: a Nonsteroidal Anti-inflammatory Drug (NSAID) and a Central Nervous System (CNS) Stimulant (Caffeine). This specific two-component composition is described as achieving pharmacological synergy compared to single-ingredient options.


Q: Does taking Coffepirine make you feel tired or drowsy?

A: Regulatory documents list nervousness and dizziness as common side effects of this medicine. Due to the Central Nervous System Stimulant component, official labeling does not typically list drowsiness or fatigue as common reactions. If dizziness or unusual effects are experienced, regulatory documents indicate caution should be exercised.


Q: Is it okay to take Coffepirine with my morning coffee?

A: Official warnings caution against consuming excessive amounts of other caffeine-containing products, which includes beverages like coffee, tea, and energy drinks. The primary reason is to mitigate the potential for synergistic stimulant effects from external caffeine sources. Official guidance emphasizes the importance of factoring in total daily caffeine intake from all sources.


Q: Are there any long-term safety concerns associated with Coffepirine use?

A: Official labeling imposes duration limits on this combination product, stating it should not be used for general pain relief lasting beyond 10 consecutive days. Prolonged use of any analgesic may be associated with medication-overuse headache (often called rebound headache), and the risks of serious gastrointestinal events also increase with duration of use.


Q: Does Coffepirine interact with common over-the-counter vitamins or supplements?

A: Regulatory documents list specific drug and product interactions, such as those with alcohol, anticoagulants, and certain prescribed medicines. While the product information advises caution with all concurrent use, specific warnings against standard vitamins or mineral supplements are not typically highlighted in the official interaction list.


Q: Is Coffepirine safe for use in older adults (seniors)?

A: Official regulatory labeling indicates that older adults are documented as having a heightened risk of serious gastrointestinal events when using this medication. Conditional use is specified for this population. The documented risk is a factor that is considered when determining the appropriateness of use in this population.


Q: Is it true that Coffepirine research focused on a certain age group?

A: Clinical trials for this medicine, including Phase II and Phase III studies, primarily concentrated on evaluating its effects in the adult population. The most robust data on efficacy and safety profiles were gathered from participants 18 years of age and older.


Q: What is the expected duration of the effects of Coffepirine?

A: The official administration guidelines for this product specify that subsequent doses, if needed, must be separated by a minimum of six hours. This dosing rule is established to maintain appropriate levels of the components in the body.


Q: Can a person stop using Coffepirine suddenly, or should it be reduced slowly?

A: Regulatory documents do not typically provide specific guidance on tapering or slow reduction when discontinuing this analgesic combination. Since it is primarily for intermittent use, specific tapering instructions for stopping its use are not commonly outlined in the official patient information.


Q: Are there different strengths or forms of Coffepirine available?

A: According to official documentation, Coffepirine is a fixed-dose combination analgesic available exclusively via the oral route as a tablet or caplet. There are standard labeled strengths for this combination product, but the official documents do not typically detail the full range of commercial availability.


Q: Is Coffepirine usage connected to any risk of bleeding?

A: Yes, official safety labeling documents a risk of bleeding. The potential for gastrointestinal bleeding, ulceration, or perforation is outlined in regulatory warnings. Furthermore, an increased bleeding risk is specifically documented when Coffepirine is combined with other medications such as anticoagulants.


Q: Is it common to have mild stomach upset when starting Coffepirine?

A: Official safety documents classify gastrointestinal effects such as nausea, dyspepsia (indigestion), and abdominal pain as commonly reported reactions. For patients who experience stomach upset, official guidelines advise that the tablets may be taken with food or milk.


Q: What should I do if I accidentally take Coffepirine too close to another medication?

A: Official information advises avoiding co-administration with numerous drug classes and sets minimum timing requirements between doses of this medicine. If an unintended timing violation or overdose occurs, official documents state that patients should immediately contact a healthcare provider or a poison control center.


Q: Are there any specific liver or kidney warnings related to Coffepirine?

A: Yes, official eligibility rules state that the medicine is absolutely contraindicated for individuals with severe heart, kidney, or liver impairment. Conditional use is also specified, requiring caution in those with mild-to-moderate hepatic or renal impairment.


Q: What kind of research studies support the use of Coffepirine?

A: The use of this combination product is supported by clinical research, including randomized, placebo-controlled studies. These trials gathered robust data on the potential for the compound to be associated with changes in symptoms and assessed its side effect profile in adult study populations.


Q: Does Coffepirine contain aspirin or caffeine?

A: Yes, regulatory quick facts confirm that Coffepirine contains two primary active ingredients: Acetylsalicylic Acid (ASA), commonly known as aspirin, and Caffeine. The formulation is a fixed-dose combination designed to utilize the effects of both components.


Q: Is Coffepirine safe for teenagers?

A: Official labeling indicates that use of Coffepirine is not advised for individuals under 18 years of age. Furthermore, official labeling restricts its use in children and teenagers recovering from viral illnesses due to the documented risk of Reye’s syndrome associated with the Acetylsalicylic Acid component.


Q: Can Coffepirine be crushed or split?

A: The official administration guidelines state that the tablets should be swallowed whole with a full glass of water. Official patient information does not mention that crushing or splitting the tablets is permitted, as this may impact the product's intended release characteristics.


Q: Why do I see Coffepirine mentioned on pain relief forums?

A: Coffepirine is officially classified as a combination analgesic with the general purpose of alleviating general discomfort and minor febrile symptoms. This classification means it is officially approved for conditions related to pain and fever.


Q: What are the key points in the 'Who can and cannot use' section?

A: Official eligibility rules state that the medicine is approved only for adults 18 years and older. It is absolutely contraindicated for those with severe heart, kidney, or liver failure, active ulcers, bleeding disorders, and during the third trimester of pregnancy. Conditional use requires caution in older adults.


Q: What types of food or drink should I be careful about when using Coffepirine?

A: Patients are advised to limit the use of excessive caffeine-containing products (like coffee, tea, and energy drinks) while taking this product to mitigate potential stimulant effects. Official warnings also caution against consuming alcohol due to the significantly increased risk of gastrointestinal bleeding.


Q: What happens if I miss a dose of Coffepirine?

A: Coffepirine is typically used only as needed to manage symptoms. If you are on a scheduled regimen and miss a dose, official guidance advises skipping the missed dose entirely and returning to your regular schedule. Patients are warned not to take two doses at one time to make up for the missed one.


Q: Does Coffepirine interfere with sleeping patterns?

A: Yes, official labeling lists insomnia (trouble sleeping) and nervousness as common side effects. This is due to the Central Nervous System Stimulant component of the medicine. Users are therefore cautioned about the potential for sleep interference.


Q: Is it safe to drive after using Coffepirine?

A: Official warnings state that caution should be used when performing tasks requiring mental alertness, such as driving or operating machinery. This is due to the listing of side effects like dizziness and vertigo, which can affect motor skills and reaction time.

How should Coffepirine be stored and disposed of?

Official Storage and Disposal Requirements

Coffepirine must be stored according to regulatory specifications to ensure stability and safety. The official requirement is to store the tablets at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product must be kept from freezing and protected from excessive heat and moisture.

To prevent the degradation of the active ingredients, the medicine must be stored in its closed container with the cap tightly secured. All medication must be kept out of the sight and reach of children to prevent accidental ingestion.

Disposal of unused or expired tablets should follow the official drug disposal hierarchy. The preferred method is to utilize an authorized drug take-back program. If this is unavailable, the medicine should be mixed with an undesirable substance (such as used coffee grounds) and placed into a sealed container before being discarded in the household trash. The product must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Coffepirine found in:

A-Z Index: